Japanese research institutes will gain access to MorphoSys’ antibody technology, while corporation retains rights to all resulting data.
MorphoSys and GeneFrontier signed an agreement focusing on therapeutic target sourcing. This is an expansion of an existing marketing alliance with GeneFrontier.
Research institutes in Japan will be offered access to MorphoSys’ HuCAL-based research antibodies against novel disease-related target molecules, while MorphoSys retains commercialization rights. Also, antibodies for selected projects will be generated by GeneFrontier using HuCAL antibody technology.
MorphoSys will have access to all research results and data around the selected research programs and the option to secure worldwide rights on such antibody programs.
In September 2004, MorphoSys and GeneFrontier signed a strategic marketing agreement to access the Japanese life science market. In 2006, both parties expanded the agreement to cover the generation of HuCAL-derived fully human antibodies for proteome research and target validation.
“GeneFrontier will now act as a hub and allow us to benefit from the research results of leading research institutes,” explains Simon Moroney, D. Phil, CEO of MorphoSys. “We are convinced that building a network of relationships with leading, medically-focused academic institutes is a productive way of accessing the therapeutic targets of tomorrow. Access to these innovative new drug targets will further strengthen MorphoSys’ proprietary drug development capabilities.”